Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?

Neesha RockwoodMaddalena CerroneMelissa BarberAndrew M HillAnton L Pozniak

Published in: Journal of the International AIDS Society (2020)

Rifabutin should be available globally as a first-line rifamycin in HIV co-infected individuals and as a switch option in cases of rifampicin associated ADRs. Further studies are needed to ascertain the utility of rifabutin in rifampicin-resistant rifabutin-susceptible TB.

Keyphrases

mycobacterium tuberculosis
pulmonary tuberculosis
hiv aids
antiretroviral therapy
human immunodeficiency virus
hiv positive
hepatitis c virus
hiv testing
emergency department
men who have sex with men
smoking cessation